Hospital
Carlsbad Medical Center LLC
Carlsbad Medical Center LLC was paid $26.47M by Medicaid between Jan 2018 and Dec 2024, across 248 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoCARLSBAD MEDICAL CENTER LLC
CARLSBAD, NM 88220
CARLSBAD, NM 88220
33aNPI1790722346assigned 06/01/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$26.47M
24GClaims527,522
24DCodes billed248
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#11 of 24
Median peer was paid$20.13M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 87,348 | $3.88M | |
| 2019 | 57,636 | $2.75M | |
| 2020 | 48,793 | $2.26M | |
| 2021 | 64,159 | $3.02M | |
| 2022 | 81,151 | $4.10M | |
| 2023 | 97,142 | $5.03M | |
| 2024incomplete | 91,293 | $5.43M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 29,136 | 27,693 | $4.60M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 19,008 | 17,814 | $3.98M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 5,983 | 5,505 | $1.70M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.4% | 3,371 | 3,227 | $1.44M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 4,152 | 3,933 | $912K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.2% | 8,056 | 7,773 | $859K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.9% | 12,029 | 10,608 | $775K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.5% | 2,286 | 2,146 | $662K |
| 71045 | Radiologic examination, chest; single view | 2.2% | 9,950 | 9,218 | $590K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 5,094 | 3,815 | $545K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 8,760 | 7,997 | $502K |
| G0378 | Hospital observation service, per hour | 1.9% | 1,128 | 1,072 | $500K |
236 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 8,172 | $465K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 7,371 | $443K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 11,037 | $377K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.4% | 2,588 | $377K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 3,454 | $356K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 919 | $318K |
| 80053 | Comprehensive metabolic panel | 1.2% | 30,322 | $305K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 4,708 | $300K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 605 | $290K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 3,264 | $281K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.0% | 6,782 | $277K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 6,677 | $270K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,555 | $234K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,011 | $229K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,177 | $224K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,734 | $187K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,382 | $183K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,636 | $164K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,621 | $162K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 744 | $160K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 480 | $157K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 649 | $126K |
| 73562 | <1% | 1,192 | $109K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,401 | $104K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 206 | $91K |
| 73610 | <1% | 872 | $90K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,261 | $85K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 804 | $83K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,388 | $80K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,600 | $77K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,926 | $77K |
| 84484 | <1% | 8,748 | $74K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,380 | $74K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,561 | $68K |
| 73130 | <1% | 725 | $64K | |
| 73030 | <1% | 719 | $63K | |
| 83880 | <1% | 2,396 | $63K | |
| 87430 | <1% | 2,457 | $59K | |
| 73630 | <1% | 743 | $55K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,175 | $54K |
| 74018 | <1% | 782 | $53K | |
| 71250 | <1% | 322 | $52K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,659 | $52K |
| 86900 | <1% | 2,576 | $52K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,306 | $47K |
| 72100 | <1% | 532 | $47K | |
| 83690 | <1% | 7,137 | $43K | |
| 81001 | <1% | 13,393 | $42K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 332 | $41K |
| 73110 | <1% | 559 | $41K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,227 | $40K |
| 81025 | <1% | 4,623 | $39K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,243 | $38K |
| 88312 | <1% | 553 | $37K | |
| 85027 | <1% | 6,185 | $36K | |
| 87040 | <1% | 4,472 | $35K | |
| 86850 | <1% | 2,778 | $35K | |
| 87186 | <1% | 3,738 | $34K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 1,579 | $34K |
| 87799 | <1% | 252 | $34K | |
| 80061 | Lipid panel | <1% | 2,664 | $33K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 83 | $33K |
| 87077 | <1% | 3,732 | $31K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,228 | $31K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,128 | $30K |
| 70486 | <1% | 124 | $29K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 999 | $28K |
| 83605 | <1% | 3,534 | $26K | |
| 87481 | <1% | 242 | $26K | |
| 82248 | <1% | 5,355 | $25K | |
| 84702 | <1% | 1,544 | $24K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,540 | $24K |
| 70498 | <1% | 57 | $23K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,579 | $22K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,465 | $22K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 391 | $21K |
| 96376 | <1% | 1,210 | $21K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,461 | $21K |
| 87420 | <1% | 1,347 | $20K | |
| 70496 | <1% | 46 | $20K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,710 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,083 | $19K |
| 86901 | <1% | 2,564 | $18K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 175 | $18K |
| 82077 | <1% | 1,714 | $18K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 681 | $17K |
| 86803 | <1% | 1,366 | $17K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 590 | $16K |
| 82962 | <1% | 5,238 | $16K | |
| 83735 | <1% | 3,970 | $16K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 36 | $15K |
| 86592 | <1% | 2,130 | $15K | |
| 85379 | <1% | 1,915 | $15K | |
| 81003 | <1% | 6,603 | $15K | |
| 87340 | <1% | 1,510 | $14K | |
| 86762 | <1% | 1,057 | $13K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 491 | $13K |
| 85610 | <1% | 3,858 | $13K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,831 | $12K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,840 | $12K |
| 84439 | <1% | 1,404 | $12K | |
| 87070 | <1% | 1,233 | $11K | |
| 93971 | <1% | 118 | $11K | |
| 76641 | <1% | 100 | $11K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 355 | $11K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 94 | $10K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 26 | $10K |
| 80179 | <1% | 825 | $10K | |
| 80143 | <1% | 806 | $10K | |
| 82550 | <1% | 1,967 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 81 | $9K |
| 86780 | <1% | 766 | $9K | |
| 88142 | <1% | 545 | $9K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 416 | $9K |
| 73080 | <1% | 116 | $9K | |
| 82150 | <1% | 1,712 | $8K | |
| 82105 | <1% | 473 | $8K | |
| 87512 | <1% | 265 | $8K | |
| 86140 | <1% | 1,910 | $8K | |
| 97010 | <1% | 683 | $8K | |
| 94760 | <1% | 1,140 | $8K | |
| 73502 | <1% | 130 | $7K | |
| 72040 | <1% | 83 | $7K | |
| 76536 | <1% | 58 | $7K | |
| 93017 | <1% | 66 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,404 | $7K |
| 84703 | <1% | 954 | $7K | |
| 73090 | <1% | 91 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 103 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 916 | $6K |
| 82607 | <1% | 469 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,028 | $6K |
| 85730 | <1% | 1,662 | $6K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 60 | $6K |
| 73590 | <1% | 91 | $6K | |
| 99152 | <1% | 84 | $6K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,217 | $6K |
| 90715 | <1% | 394 | $6K | |
| 82950 | <1% | 1,261 | $6K | |
| 73140 | <1% | 74 | $6K | |
| 86787 | <1% | 575 | $6K | |
| 97164 | <1% | 241 | $5K | |
| 87081 | <1% | 743 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,172 | $5K |
| 74178 | <1% | 14 | $5K | |
| 82553 | <1% | 766 | $5K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 26 | $5K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 986 | $5K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 336 | $4K |
| 84481 | <1% | 271 | $4K | |
| 97161 | <1% | 111 | $4K | |
| 82775 | <1% | 167 | $4K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 244 | $4K |
| 83789 | <1% | 167 | $4K | |
| 83021 | <1% | 188 | $4K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 301 | $3K |
| 83874 | <1% | 484 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 707 | $3K |
| 87205 | <1% | 762 | $3K | |
| 85652 | <1% | 1,369 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 470 | $3K |
| 82261 | <1% | 167 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $3K |
| 81513 | <1% | 31 | $3K | |
| 82016 | <1% | 167 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 75 | $3K |
| 82128 | <1% | 167 | $3K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 22 | $2K |
| D7250 | <1% | 16 | $2K | |
| H0049 | Alcohol and/or drug screening | <1% | 149 | $2K |
| 82247 | <1% | 362 | $2K | |
| 83540 | <1% | 375 | $2K | |
| 74019 | <1% | 12 | $2K | |
| 80074 | <1% | 40 | $2K | |
| 82760 | <1% | 167 | $2K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 465 | $2K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 398 | $2K |
| 96367 | <1% | 39 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 342 | $2K |
| 82803 | <1% | 106 | $2K | |
| 82140 | <1% | 160 | $2K | |
| 74022 | <1% | 17 | $1K | |
| 82677 | <1% | 47 | $1K | |
| 84403 | <1% | 64 | $1K | |
| 72110 | <1% | 12 | $1K | |
| 97162 | <1% | 41 | $1K | |
| 82746 | <1% | 99 | $1K | |
| 12011 | <1% | 14 | $1K | |
| 82728 | <1% | 107 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 221 | $1K |
| 87899 | <1% | 48 | $1K | |
| 84437 | <1% | 167 | $1K | |
| 88304 | <1% | 54 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 54 | $1K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 132 | $952.57 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 307 | $923.69 |
| 76642 | <1% | 13 | $907.49 | |
| 86336 | <1% | 47 | $906.10 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 646 | $890.77 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 26 | $881.74 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 253 | $875.68 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 133 | $865.98 |
| 73060 | <1% | 12 | $846.14 | |
| 85018 | <1% | 267 | $812.31 | |
| C1769 | Guide wire | <1% | 42 | $811.21 |
| 85014 | <1% | 262 | $797.12 | |
| 96368 | <1% | 56 | $706.04 | |
| 83655 | <1% | 41 | $667.89 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 37 | $655.82 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 164 | $628.41 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 13 | $582.17 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 86 | $477.21 |
| 87521 | Neg quan hep c or qual rna | <1% | 13 | $471.92 |
| 84100 | <1% | 206 | $438.91 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 37 | $417.06 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 38 | $407.61 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 55 | $321.09 |
| 84466 | <1% | 30 | $308.11 | |
| 84550 | <1% | 70 | $304.53 | |
| 84402 | <1% | 12 | $283.28 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 16 | $232.41 |
| 99153 | Mod sedat endo service >5yrs | <1% | 12 | $210.28 |
| 87015 | <1% | 27 | $204.65 | |
| 87046 | <1% | 26 | $198.92 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 14 | $179.39 |
| 86038 | <1% | 17 | $177.83 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 17 | $170.29 |
| 86376 | <1% | 13 | $155.53 | |
| 87045 | <1% | 13 | $99.46 | |
| 84156 | <1% | 29 | $94.80 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 18 | $76.37 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 12 | $56.03 |
| 86430 | <1% | 12 | $51.19 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 39 | $50.85 |
| 82010 | <1% | 13 | $43.03 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 15 | $18.76 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.